Alkem Laboratories
Alkem Laboratories Share Price Chart
Alkem Laboratories last traded at ₹5,201.00 (2026-10-13). Over the past month the stock moved +1.8%, three months the stock moved -3.3%, year the stock moved -6.1%. Its closing range over 52 weeks is ₹5,089.50 – ₹5,836.50, with the latest close 10.9% below the high.
Closing prices up to 2026-10-13.
About Alkem Laboratories
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Leading Pharmaceutical company[1] Alkem Laboratories holds a 4.1% market share in the Indian domestic formulation market as of 9M FY25, making it the 5th largest pharmaceutical company in India. The company maintains its #1 position in anti-infectives and has a strong presence in gastrointestinal, pain management, vitamins, minerals, and nutrients segments while also expanding in chronic therapies like neurology, cardiology, and diabetology.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Alkem Laboratories reported sales of ₹3,740.00 crore (+10.9%) and net profit of ₹521.00 crore (-22.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 3,740 | 766.00 | 20.00 | 521.00 | 43.49 |
| Mar 2026 | 3,603 | 517.00 | 14.00 | 251.00 | 19.78 |
| Dec 2025 | 3,737 | 828.00 | 22.00 | 653.00 | 53.19 |
| Sep 2025 | 4,001 | 921.00 | 23.00 | 779.00 | 63.99 |
| Jun 2025 | 3,371 | 739.00 | 22.00 | 668.00 | 55.56 |
| Mar 2025 | 3,144 | 391.00 | 12.00 | 322.00 | 25.58 |
| Dec 2024 | 3,374 | 759.00 | 23.00 | 641.00 | 52.34 |
| Sep 2024 | 3,415 | 753.00 | 22.00 | 702.00 | 57.60 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -0.7% | +1.5% | +7.1% | +11.2% | +17.2% | +10.8% | +14.6% | +10.9% |
| Operating profit growth | +0.8% | +7.2% | -2.7% | +21.3% | +22.3% | +9.1% | +32.2% | +3.7% |
| Net profit growth | +14.1% | +6.1% | +5.9% | +21.5% | +11.0% | +1.9% | -22.0% | -22.0% |
| EPS growth | +11.0% | +5.2% | +4.2% | +21.8% | +11.1% | +1.6% | -22.7% | -21.7% |
| OPM % | 22.0% | 23.0% | 12.0% | 22.0% | 23.0% | 22.0% | 14.0% | 20.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Alkem Laboratories reported sales of ₹14,712.00 crore (+13.5%) and net profit of ₹2,351.00 crore (+6.1%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 14,712 | 3,005 | 20.00 | 2,351 | 192.51 |
| Mar 2025 | 12,965 | 2,512 | 19.00 | 2,215 | 181.11 |
| Mar 2024 | 12,668 | 2,249 | 18.00 | 1,811 | 150.19 |
| Mar 2023 | 11,599 | 1,622 | 14.00 | 1,007 | 82.31 |
| Mar 2022 | 10,634 | 2,054 | 19.00 | 1,680 | 137.63 |
| Mar 2021 | 8,865 | 1,945 | 22.00 | 1,618 | 132.57 |
| Mar 2020 | 8,344 | 1,476 | 18.00 | 1,149 | 94.26 |
| Mar 2019 | 7,357 | 1,120 | 15.00 | 774.00 | 63.61 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +14.9% | +13.4% | +6.2% | +20.0% | +9.1% | +9.2% | +2.3% | +13.5% |
| Operating profit growth | +11.0% | +31.8% | +31.8% | +5.6% | -21.0% | +38.7% | +11.7% | +19.6% |
| Net profit growth | +21.3% | +48.4% | +40.8% | +3.8% | -40.1% | +79.8% | +22.3% | +6.1% |
| EPS growth | +20.5% | +48.2% | +40.6% | +3.8% | -40.2% | +82.5% | +20.6% | +6.3% |
| OPM % | 15.0% | 18.0% | 22.0% | 19.0% | 14.0% | 18.0% | 19.0% | 20.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Alkem Laboratories.
Get Free AI Stock Analysis FREE →Latest News
-
Alkem Labs Pivots to Medtech, CDMO Amid Earnings Normalization Alkem Laboratories is diversifying into medtech and CDMO services to find new growth engines beyond its core pharma business. While the company maintains a strong cash position, investors should note that these new s…
-
Alkem Laboratories shares fall over 2% after CFO Nitin Agrawal resigns - Moneycontrol.com
-
Alkem Laboratories shares fall over 2% after CFO Nitin Agrawal resigns - Moneycontrol.com
-
Alkem Laboratories Launches Epilepsy Drug NeuCeno in India
-
Alkem Laboratories inches up on launching NeuCeno for treatment of partial-onset seizures in adult patients
-
Alkem Laboratories launches NeuCeno for treatment of partial-onset seizures in adult patients
-
Alkem Laboratories launches Ginsenoside Exosome-based hair growth serum ‘Renocia Exo’
-
Alkem Laboratories launches Ginsenoside Exosome-based hair growth serum ‘Renocia Exo’
-
Alkem Laboratories launches Ginsenoside Exosome-based hair growth serum ‘Renocia Exo’
-
Alkem Laboratories launches Ginsenoside Exosome-based hair growth serum ‘Renocia Exo’
Frequently Asked Questions
What is Alkem Laboratories's current stock price?
Alkem Laboratories shares were last quoted at ₹5,201.00 (-1.5% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Alkem Laboratories?
Alkem Laboratories has a price-to-earnings (P/E) ratio of 28.65 and a price-to-book (P/B) ratio of 4.31. The industry P/E is 53.33.
What is the 52-week high and low of Alkem Laboratories?
The 52-week high of Alkem Laboratories is ₹5,933.00 and the 52-week low is ₹5,052.05.
What is the market cap of Alkem Laboratories?
The market capitalisation of Alkem Laboratories is about ₹61,804.34 crore.
How did Alkem Laboratories perform in its latest quarterly results?
In the latest quarter (Jun 2026), Alkem Laboratories reported sales of ₹3,740.00 crore (+10.9%) and net profit of ₹521.00 crore (-22.0%), compared with the same quarter last year.
Is Alkem Laboratories a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Alkem Laboratories has a 3-year ROE of 19.00%, 3-year profit growth of 32.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Alkem Laboratories?
Promoters hold about 49.70% of Alkem Laboratories.
Which sector does Alkem Laboratories belong to?
Alkem Laboratories belongs to the Pharmaceuticals & Drugs sector.